A systematic review of real-world evidence described 70 eyes of 63 patients with retinal vasculitis or vascular occlusion following treatment with brolucizumab for neovascular age-related macular degeneration.
Approximately half of these events occurred after one injection, and more than one-third were the cause of reduced vision. Two-thirds of the cases were in women.
“Brolucizumab is a remarkably powerful anti-VEGF agent, and while it is not commonly utilized in clinical practice due to known risks of intraocular inflammation, retinal vasculitis and retinal vascular occlusions, it is